Maximal Oxygen Uptake and Ventilation Improvement Following Sacubitril-Valsartan Therapy
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.17/3533 |
Resumo: | Background: Sacubitril/valsartan had its prognosis benefit confirmed in the PARADIGM-HF trial. However, data on cardiopulmonary exercise testing (CPET) changes with sacubitril-valsartan therapy are scarce. Objective: This study aimed to compare CPET parameters before and after sacubitril-valsartan therapy. Methods: Prospective evaluation of chronic heart failure (HF) patients with left ventricular ejection fraction ≤40% despite optimized standard of care therapy, who started sacubitril-valsartan therapy, expecting no additional HF treatment. CPET data were gathered in the week before and 6 months after sacubitril-valsartan therapy. Statistical differences with a p-value <0.05 were considered significant. Results: Out of 42 patients, 35 (83.3%) completed the 6-month follow-up, since 2 (4.8%) patients died and 5 (11.9%) discontinued treatment for adverse events. Mean age was 58.6±11.1 years. New York Heart Association class improved in 26 (74.3%) patients. Maximal oxygen uptake (VO2max) (14.4 vs. 18.3 ml/kg/min, p<0.001), VE/VCO2slope (36.7 vs. 31.1, p<0.001), and exercise duration (487.8 vs. 640.3 sec, p<0.001) also improved with sacubitril-valsartan. Benefit was maintained even with the 24/26 mg dose (13.5 vs. 19.2 ml/kg/min, p=0.018) of sacubitril-valsartan, as long as this was the highest tolerated dose. Conclusions: Sacubitril-valsartan therapy is associated with marked CPET improvement in VO2max, VE/VCO2slope, and exercise duration. |
id |
RCAP_3dd08a68331fadf1bd8dcc5b1d2ac01d |
---|---|
oai_identifier_str |
oai:repositorio.chlc.min-saude.pt:10400.17/3533 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Maximal Oxygen Uptake and Ventilation Improvement Following Sacubitril-Valsartan TherapyMelhora no Consumo Máximo de Oxigênio e na Ventilação após Tratamento com Sacubitril-ValsartanaHSM CARAminobutyratesAgedAngiotensin Receptor AntagonistsDrug CombinationsHeart Failure / drug therapyHumansMiddle AgedProspective StudiesOxygenStroke VolumeTetrazolesTreatment OutcomeVentricular Function, LeftBackground: Sacubitril/valsartan had its prognosis benefit confirmed in the PARADIGM-HF trial. However, data on cardiopulmonary exercise testing (CPET) changes with sacubitril-valsartan therapy are scarce. Objective: This study aimed to compare CPET parameters before and after sacubitril-valsartan therapy. Methods: Prospective evaluation of chronic heart failure (HF) patients with left ventricular ejection fraction ≤40% despite optimized standard of care therapy, who started sacubitril-valsartan therapy, expecting no additional HF treatment. CPET data were gathered in the week before and 6 months after sacubitril-valsartan therapy. Statistical differences with a p-value <0.05 were considered significant. Results: Out of 42 patients, 35 (83.3%) completed the 6-month follow-up, since 2 (4.8%) patients died and 5 (11.9%) discontinued treatment for adverse events. Mean age was 58.6±11.1 years. New York Heart Association class improved in 26 (74.3%) patients. Maximal oxygen uptake (VO2max) (14.4 vs. 18.3 ml/kg/min, p<0.001), VE/VCO2slope (36.7 vs. 31.1, p<0.001), and exercise duration (487.8 vs. 640.3 sec, p<0.001) also improved with sacubitril-valsartan. Benefit was maintained even with the 24/26 mg dose (13.5 vs. 19.2 ml/kg/min, p=0.018) of sacubitril-valsartan, as long as this was the highest tolerated dose. Conclusions: Sacubitril-valsartan therapy is associated with marked CPET improvement in VO2max, VE/VCO2slope, and exercise duration.Sociedade Brasileira de CardiologiaRepositório do Centro Hospitalar Universitário de Lisboa Central, EPEValentim Gonçalves, APereira-da-Silva, TGalrinho, ARio, PSoares, RMFeliciano, JIlhão Moreira, RSilva, SAlves, SCapilé, ECruz Ferreira, R2020-12-15T15:59:55Z2020-112020-11-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.17/3533engArq Bras Cardiol. 2020 Nov;115(5):821-827.10.36660/abc.20190443info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-03-10T09:43:27Zoai:repositorio.chlc.min-saude.pt:10400.17/3533Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:20:50.662207Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Maximal Oxygen Uptake and Ventilation Improvement Following Sacubitril-Valsartan Therapy Melhora no Consumo Máximo de Oxigênio e na Ventilação após Tratamento com Sacubitril-Valsartana |
title |
Maximal Oxygen Uptake and Ventilation Improvement Following Sacubitril-Valsartan Therapy |
spellingShingle |
Maximal Oxygen Uptake and Ventilation Improvement Following Sacubitril-Valsartan Therapy Valentim Gonçalves, A HSM CAR Aminobutyrates Aged Angiotensin Receptor Antagonists Drug Combinations Heart Failure / drug therapy Humans Middle Aged Prospective Studies Oxygen Stroke Volume Tetrazoles Treatment Outcome Ventricular Function, Left |
title_short |
Maximal Oxygen Uptake and Ventilation Improvement Following Sacubitril-Valsartan Therapy |
title_full |
Maximal Oxygen Uptake and Ventilation Improvement Following Sacubitril-Valsartan Therapy |
title_fullStr |
Maximal Oxygen Uptake and Ventilation Improvement Following Sacubitril-Valsartan Therapy |
title_full_unstemmed |
Maximal Oxygen Uptake and Ventilation Improvement Following Sacubitril-Valsartan Therapy |
title_sort |
Maximal Oxygen Uptake and Ventilation Improvement Following Sacubitril-Valsartan Therapy |
author |
Valentim Gonçalves, A |
author_facet |
Valentim Gonçalves, A Pereira-da-Silva, T Galrinho, A Rio, P Soares, RM Feliciano, J Ilhão Moreira, R Silva, S Alves, S Capilé, E Cruz Ferreira, R |
author_role |
author |
author2 |
Pereira-da-Silva, T Galrinho, A Rio, P Soares, RM Feliciano, J Ilhão Moreira, R Silva, S Alves, S Capilé, E Cruz Ferreira, R |
author2_role |
author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
Repositório do Centro Hospitalar Universitário de Lisboa Central, EPE |
dc.contributor.author.fl_str_mv |
Valentim Gonçalves, A Pereira-da-Silva, T Galrinho, A Rio, P Soares, RM Feliciano, J Ilhão Moreira, R Silva, S Alves, S Capilé, E Cruz Ferreira, R |
dc.subject.por.fl_str_mv |
HSM CAR Aminobutyrates Aged Angiotensin Receptor Antagonists Drug Combinations Heart Failure / drug therapy Humans Middle Aged Prospective Studies Oxygen Stroke Volume Tetrazoles Treatment Outcome Ventricular Function, Left |
topic |
HSM CAR Aminobutyrates Aged Angiotensin Receptor Antagonists Drug Combinations Heart Failure / drug therapy Humans Middle Aged Prospective Studies Oxygen Stroke Volume Tetrazoles Treatment Outcome Ventricular Function, Left |
description |
Background: Sacubitril/valsartan had its prognosis benefit confirmed in the PARADIGM-HF trial. However, data on cardiopulmonary exercise testing (CPET) changes with sacubitril-valsartan therapy are scarce. Objective: This study aimed to compare CPET parameters before and after sacubitril-valsartan therapy. Methods: Prospective evaluation of chronic heart failure (HF) patients with left ventricular ejection fraction ≤40% despite optimized standard of care therapy, who started sacubitril-valsartan therapy, expecting no additional HF treatment. CPET data were gathered in the week before and 6 months after sacubitril-valsartan therapy. Statistical differences with a p-value <0.05 were considered significant. Results: Out of 42 patients, 35 (83.3%) completed the 6-month follow-up, since 2 (4.8%) patients died and 5 (11.9%) discontinued treatment for adverse events. Mean age was 58.6±11.1 years. New York Heart Association class improved in 26 (74.3%) patients. Maximal oxygen uptake (VO2max) (14.4 vs. 18.3 ml/kg/min, p<0.001), VE/VCO2slope (36.7 vs. 31.1, p<0.001), and exercise duration (487.8 vs. 640.3 sec, p<0.001) also improved with sacubitril-valsartan. Benefit was maintained even with the 24/26 mg dose (13.5 vs. 19.2 ml/kg/min, p=0.018) of sacubitril-valsartan, as long as this was the highest tolerated dose. Conclusions: Sacubitril-valsartan therapy is associated with marked CPET improvement in VO2max, VE/VCO2slope, and exercise duration. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-12-15T15:59:55Z 2020-11 2020-11-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.17/3533 |
url |
http://hdl.handle.net/10400.17/3533 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Arq Bras Cardiol. 2020 Nov;115(5):821-827. 10.36660/abc.20190443 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Cardiologia |
publisher.none.fl_str_mv |
Sociedade Brasileira de Cardiologia |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799131304769355776 |